MAXCYTE INC. - COMMON STOCK

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

30 Jan 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

23 Jan 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

08 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

03 Jan 2024 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

02 Jan 2024 01:00:00 By Nasdaq GlobeNewswire

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

11 Dec 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

16 Nov 2023 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

08 Nov 2023 15:05:01 By Nasdaq GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

06 Nov 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

04 Oct 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

06 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

05 Sep 2023 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

09 Aug 2023 15:05:01 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

01 Aug 2023 07:05:51 By Nasdaq GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

13 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

10 Jul 2023 07:05:00 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

06 Jul 2023 07:05:05 By Nasdaq GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

01 Jun 2023 15:05:00 By Nasdaq GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

10 May 2023 15:05:01 By Nasdaq GlobeNewswire

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

04 May 2023 07:05:53 By Nasdaq GlobeNewswire